In both male and female mice, LD-IL-2 treatment not only reverses NTG and sumatriptan-induced persistent facial skin hypersensitivity, but also prevents the development of hyperalgesic priming, which is mechanistically related to the transition from episodic to chronic headache [12]. Here, IL2 is linked to Headache.